Clinical Trials Logo

Filter by:
NCT ID: NCT03992183 Active, not recruiting - Clinical trials for Pulmonary Nodule, Solitary

Utility of CAML as Diagnostic for Early Stage Lung Cancer

Start date: May 21, 2019
Phase:
Study type: Observational

Primary Objective Determine the prevalence of CAMLS in patients with pulmonary nodules. Secondary Objectives Determine the positive and negative predictive value of CAMLS in patients with pulmonary nodules who undergo biopsy. Model combinations of clinical factors with the presence/absence of CAMLS to refine strategies for assessment of patients with pulmonary nodules. Evaluate whether these measures result in enhanced T-cell activity and/or NK cell function and number

NCT ID: NCT03991156 Active, not recruiting - Anesthesia Clinical Trials

AVATAR Anesthesia Alternative in Pediatric Radiotherapy: A Multi-Center Study

Start date: May 28, 2019
Phase:
Study type: Observational

To determine the success rate of the AVATAR audio-visual system. All patients enrolled in the study will be counted, and each patient who is able to undergo at least one fraction without anesthesia will count as a success while each patient who does not have at least one fraction without anesthesia will count as a failure. The success rate will be the proportion of patients who are successes.

NCT ID: NCT03990610 Active, not recruiting - Breast Carcinoma Clinical Trials

An Investigational Surgical Procedure (Vascularized Lymph Node Transfer) in Reducing the Risk of Lymphedema in Patients With Breast Cancer Undergoing Breast Reconstruction

Start date: May 24, 2019
Phase: N/A
Study type: Interventional

This trial studies how an investigational surgical procedure called vascularized lymph node transfer works in lowering the risk of arm swelling (lymphedema) in patients with breast cancer undergoing breast reconstruction. Patients who undergo breast reconstruction are often at high risk of developing lymphedema. Vascularized lymph node transfer involves transferring lymph nodes from an unaffected area of the body to replace those removed as part of treatment, which may lower the risk of lymphedema after breast reconstruction.

NCT ID: NCT03989986 Active, not recruiting - Sickle Cell Disease Clinical Trials

iPeer2Peer Program for Youth With Sickle Cell Disease

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

The iPeer2Peer Sickle Cell Disease (SCD) study matches youth (12-18 years of age) with SCD to a mentor (trained young adult) who has learned to manage their SCD well, transitioned to adult care, and can support youth participants emotionally and socially. Participants will be randomly assigned one of two groups, either (1) The intervention group: Study group participants are matched with a mentor for 15 weeks, and are expected to have up to ten calls with one another; (2) The control group: This study group will be on a 15 week waitlist to receive a mentor. This study will first assess the feasibility of conducting this research with youth with SCD. Also, this study will assess the preliminary effectiveness of peer mentorship by comparing various health outcomes of the two study groups post-intervention.

NCT ID: NCT03989947 Active, not recruiting - Achondroplasia Clinical Trials

An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia

Start date: June 12, 2019
Phase: Phase 2
Study type: Interventional

This is a Phase 2, open-label multi-center long-term extension study, with approximately 70 subjects, to evaluate the safety and efficacy of BMN111 in children with Achondroplasia until subjects reach near-adult final height. Eligible subjects will have completed 1 year of BMN111 or placebo treatment in the 111-206 study and once enrolled in the 111-208 extension study will receive a daily dose of BMN111 by subcutaneous injection according to their age as determined by 111-206.

NCT ID: NCT03989466 Active, not recruiting - Clinical trials for T-Cell Prolymphocytic Leukemia

Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia

Start date: January 15, 2020
Phase: Phase 1
Study type: Interventional

This phase Ib trial studies the side effects and best dose of alemtuzumab when given together with itacitinib in treating patients with T-cell prolymphocytic leukemia. Itacitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with alemtuzumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving itacitinib and alemtuzumab may work better in treating patients with T-cell prolymphocytic leukemia compared to standard of care treatment.

NCT ID: NCT03989414 Active, not recruiting - Multiple Myeloma Clinical Trials

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Start date: September 30, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

NCT ID: NCT03989206 Active, not recruiting - Clinical trials for Moderate-to-Severe Atopic Dermatitis

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Start date: December 30, 2019
Phase: Phase 3
Study type: Interventional

Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description

NCT ID: NCT03989128 Active, not recruiting - Pain Clinical Trials

Survey of Cancer Patients' Perceptions of Difficulties Encountered When Filling Opioid Prescriptions

Start date: April 23, 2019
Phase:
Study type: Observational

This trial studies the problems that cancer patients face when filling prescriptions for opioids (medications that are used to manage pain). Pain is one of the most common symptoms among cancer patients. Opioid therapy is generally the treatment of choice for adequate management of cancer-related pain. Knowledge of these problems may help health care providers assess the most effective treatment options for cancer patients, and inform policy makers of the adjustments that need to be made to regulations to ensure cancer patients don't lose their access to opioids.

NCT ID: NCT03988699 Active, not recruiting - Tinnitus Clinical Trials

Novel Tinnitus Implant System for the Treatment of Chronic Severe Tinnitus

Start date: August 23, 2021
Phase: N/A
Study type: Interventional

Researchers are gathering information on the safety and effectiveness of a novel device called the Tinnitus Implant System for the treatment of tinnitus.